E-0702 is an antipseudomonal cephalosporin derivative which has a broad spectrum of antibacterial activity against clinical isolates of gram-positive and gram-negative bacteria. Its in vitro antibacterial activities were less than those of cefoperazone and cefotaxime against Staphylococcus aureus and Staphylococcus epidermidis, but were significantly high against gram-negative bacteria including the Pseudomonas group. It was most characteristic that E-0702 showed high antibacterial activity against Pseudomonas aeruginosa. E-0702 was relatively stable to inactivation by plasmid-mediated penicillinases and cephalosporinases produced by gram-negative bacteria.
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Many new cephalosporins with a broad antibacterial spectrum have been developed in the past few years. Several of these antibiotics have been in clinical use for the treatment of a wide range of bacterial infections. E-0702, (6R, 7R)-3-[(1 -carboxymethyl -1H -tetrazol -5 -yl) - (Fig. 1) , is a new antipseudomonal cephalosporin derivative with a broad antibacterial spectrum, developed by Eisai Co., Ltd., Tokyo, Japan. The current report summarizes the results of studies of the in vitro antibacterial activity and P-lactamase stability of this new cephalosporin with clinical isolates stocked in this laboratory.
MATERIALS AND METHODS
Antibiotics. E-0702 was synthesized in the research laboratories of Eisai Co. As comparative compounds, cefoperazone (CFP) and cefotaxime (CTX) were supplied by Toyama Chemical Co., Japan, and Hoechst Japan Ltd., Japan, respectively. Cephaloridine, cefazolin, and penicillin G (PCG) were obtained commercially.
Organisms. The strains of gram-positive and gramnegative bacteria used in this study were isolated from clinical materials in Japan between 1979 and 1981 and have been maintained since isolation in the Laboratory of Drug Resistance in Bacteria, Gunma University, Japan.
Media. Sensitivity test (ST) agar, ST broth (Nissui Seiyaku Co., Japan), and nutrient agar containing bromothymol blue and lactose were used. For the dilution of cell suspensions, buffered saline containing 0.01% gelatin (1) Tenfold-diluted cultures were inoculated in ST broth containing twofold serial dilutions of a drug. MICs were read after incubation at 370C for 18 h. One loopful (about 0.01 ml) of each culture tube in the MIC test series was spotted onto drug-free bromothymol blue agar plates. After incubation at 37°C for 18 h, the minimal bactericidal concentrations (MBCs) of antibiotic were estimated as the lowest concentrations that did not allow the formation of colonies.
Susceptibility to 13-lactamase. Chromosomally mediated and plasmid-mediated 1-lactamases used in this study were purified by methods described previously RESULTS Antibacterial activity. The in vitro activity of E-0702 against gram-positive and gram-negative bacteria was compared with those of CFP and CTX (Table 1) . Against both Staphylococcus aureus and Staphylococcus epidermidis, E-0702 was less active than other antibiotics. On the other hand, E-0702 was more active than CFP against gram-negative bacteria except N. gonorrhoeae. However, 90% of N. gonorrhoeae strains were inhibited by 0.5 ,ug of E-0702 per ml. The concentrations of E-0702 required to inhibit the growth of 90% of organisms of Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae were 0.08, 0.19, and 2.20 ,ug/ml, respectively, indicating that E-0702 was 10-to 25-fold more potent than CFP and similar to CTX. E-0702 was also highly active against Serratia marcescens, Proteus mirabilis, and indole-positive Proteus species. The activity of E-0702 against S. marcescens and Proteus inconstans was greater than that of CFP and similar to that of CTX. Against P. mirabilis, Proteus morganii, Proteus vulgaris, and Proteus rettgeri, E-0702 was some 10-fold more active than CFP but slightly less active than CTX. E-0702 was the most active compound tested against Citrobacterfreundii and Salmonella species.
The activity of E-0702 against Pseudomonas aeruginosa and Acinetobacter calcoaceticus was remarkable: 90% of the strains of these species were inhibited by E-0702 at concentrations of 0.45 and 0.98 ,ug/ml, respectively. It was found that E-0702 was also the most effective compound against the other Pseudomonas species.
Bactericidal activity. The bactericidal activities of E-0702 were compared with those of CFP against representative strains of S. marcescens and P. aeruginosa (Fig. 2) . Against S. marcescens IAM1184, E-0702 and CFP were bactericidal at concentrations of 0.8 and 1.56 ,ug/ml, respectively. Against P. aeruginosa PAOI, however, E-0702 displayed a much higher bacte- Susceptibility to 13-lactamase. The maximum rates of hydrolysis (Vmax) of the five cephalosporins and PCG are presented in Table 3 . E-0702 was stable to various types of cephalosporinases produced by E. coli (7), E. cloacae (8), C.
freundii (15), P. aeruginosa (10), and P. rettgeri (6) . The compound also showed a high stability to penicillinase (PCase) types II (2) and III (oxacillin-hydrolyzing PCase; 17) and type IV (carbenicillin-hydrolyzing PCase; 14). However, E-0702 was partially hydrolyzed by PCase type I (TEM-type PCase; 3), P. morganii cephalosporinase (16) , and the cefuroxime-hydrolyzing 1-lactamases (9) produced by P. vulgaris (5), Pseudomonas cepacia (4), and Bacteroides fragilis (13) . The stability of E-0702 to 1-lactamase was almost the same as that of CFP. DISCUSSION E-0702 is a new parenteral cephalosporin with a broad spectrum of antibacterial activity. This study shows that, with the exception of N. gonorrhoeae, E-0702 is more active than CFP against gram-negative bacteria isolated from clinical specimens. A notable characteristic of E-0702 is that this compound has a marked advantage over the other cephalosporins with respect to activity against P. aeruginosa, being 20-to 110-fold more active than CFP and CTX. Furthermore, E-0702 also has remarkable activity in vitro against Salmonella species, C. freundii, and A. calcoaceticus. E-0702 is less active in vitro against staphylococci than against gramnegative bacteria. 
